We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » GSK Gets New Jemperli Approval for Mismatch Repair-Deficient Tumors
GSK Gets New Jemperli Approval for Mismatch Repair-Deficient Tumors
The FDA has granted GlaxoSmithKline’s (GSK) monoclonal antibody Jemperli (dostarlimab) an expanded indication for treating adults with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors, usually found in endometrial, colorectal or other gastrointestinal cancers.